Navigation Links
UNC team finds new target for treatment of advanced prostate cancer
Date:7/6/2010

Chapel Hill, NC In its early stages, prostate cancer requires androgens (hormones that promote the development and maintenance of male sex characteristics) for growth, and current first-line therapies target the receptor for these hormones to slow cancer's development and spread.

However, advanced prostate cancers are often androgen-independent, meaning that androgen-blocking therapies are ineffective.

Scientists aren't sure how this shift occurs as prostate cancer advances. One idea is that prostate cancer cells acquire the ability to make their own androgen. Another says that the androgen receptor that is known to stimulate tumor growth can still be active even when the hormone is not present. Most likely, both are important.

A recent study by UNC researchers, published in the Journal of Biological Chemistry, provides evidence for the second theory, demonstrating that expression of one of a group of genes found only in humans and non-human primates can promote androgen receptor activity in concert with other proteins called coregulators.

One of a group of MAGE genes, so named because they were originally identified in melanoma, called MAGE-11 interacts with another protein, called p300, to provide the cancer cells with a way to enhance androgen receptor signaling and promote tumor growth, even when patients are undergoing androgen deprivation therapy.

According to team leader Elizabeth M. Wilson, PhD, professor of pediatrics and biochemistry and biophysics at UNC-Chapel Hill, "We found that a small portion of the androgen receptor interacts with the MAGE-11 molecule which serves as a bridge to p300, a strong histone modifying enzyme that increases androgen receptor activity. This is exciting because it shows how the cancer cells have developed a way to boost androgen receptor activity, even in the absence or at low levels of the hormone that binds the androgen receptor."

Wilson, who is also a UNC Lineberger member, goes on to explain that understanding this mechanism opens the door to additional targets for new therapies and broader clinical applications of new drugs.

"The MAGE-11 molecule is a promising target for shutting down androgen receptor activity that promotes the growth of cancer cells," she adds.


'/>"/>

Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina School of Medicine
Source:Eurekalert

Related biology news :

1. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
2. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
3. Study finds blocking angiogenesis signaling from inside cell may lead to serious health problems
4. Study finds Viagra increases release of key reproductive hormone
5. Survey finds elevated rates of new asthma among WTC rescue and recovery workers
6. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
7. Study finds a high rate of asthma in college athletes
8. Ecologist finds dire devastation of snake species following floods of 93, 95
9. Men shed light on the mystery of human longevity, study finds
10. JILA finds flaw in model describing DNA elasticity
11. Americans remain pessimistic about the environment, Stanford-AP survey finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... robotic gym for the rehabilitation and functional motor sense evaluation of lower ... . The first 30 robots will be available from June in ... The technology was developed and patented at the IIT laboratories and has ... to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. The ... Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, industry ... officials from around the world to address key issues in device compliance, quality and ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
(Date:10/9/2017)... SAN DIEGO , Oct. 9, 2017 /PRNewswire/ ... a biological mechanism by which its ProCell stem ... of critical limb ischemia.  The Company, demonstrated that ... the amount of limbs saved as compared to ... of the molecule HGF resulted in reduction of ...
Breaking Biology Technology: